Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Invinity-ADC
- Development stage
- Preclinical
- Lead developer
- Inventera
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
01
Overview
Invinity-ADC is a preclinical-stage antibody-drug conjugate (ADC) being developed by Inventera. It is built upon the company's proprietary Invinity™ platform, a polysaccharide-based nanoparticle drug delivery system designed to overcome common nanomedicine challenges such as immune cell phagocytosis (macrophage clearance), protein corona formation, and particle aggregation. By utilizing the Invinity™ platform as a linker/carrier, the technology aims to increase the drug-to-antibody ratio (DAR) and improve the solubility and stability of hydrophobic payloads without compromising safety. The specific antibody targets and small-molecule payloads for Invinity-ADC have not been publicly disclosed, but the platform is being evaluated for therapeutic applications in oncology.
- Other names
- Invinity antibody-drug conjugateInvinity™-ADC
Beyond the preview
Go deeper on Invinity-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Invinity-ADC.